BMC pharmacology & toxicology
-
BMC Pharmacol Toxicol · Sep 2013
Multicenter StudyActive post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.
After several exploratory and confirmatory clinical trials, the intralesional administration of human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced diabetic foot ulcers (DFU). The aim of this work was to evaluate the effectiveness and safety of this procedure in medical practice. ⋯ The favorable benefit/risk balance, confirms the beneficial clinical profile of intralesional hrEGF in the treatment of DFUs.